Literature DB >> 21828116

An OHSS-Free Clinic by segmentation of IVF treatment.

Paul Devroey1, Nikolaos P Polyzos, Christophe Blockeel.   

Abstract

Published data indicate a significant increase in ovarian hyperstimulation syndrome globally. The occurrence of approximately three maternal deaths per 100,000 stimulated women has been reported, and extrapolation of these figures to a global situation would give an impressive number. The syndrome can be erased by applying ovarian stimulation using the combination of GnRH antagonist with GnRH agonist to trigger ovulation. In this case, the strategy is to freeze all of the oocytes or embryos for later use.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828116     DOI: 10.1093/humrep/der251

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  106 in total

1.  Does freeze all policy eliminate OHSS??? "It ain't necessarily so…".

Authors:  Zeev Blumenfeld
Journal:  J Assist Reprod Genet       Date:  2015-09-07       Impact factor: 3.412

2.  Agonist depot versus OCP programming of frozen embryo transfer: a retrospective analysis of freeze-all cycles.

Authors:  Kemal Ozgur; Murat Berkkanoglu; Hasan Bulut; Peter Humaidan; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2015-12-23       Impact factor: 3.412

3.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

4.  GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome.

Authors:  Sherif A Hebisha; Banan A Aboelazm; H N Sallam
Journal:  J Obstet Gynaecol India       Date:  2016-11-29

Review 5.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

6.  The health risks of ART.

Authors:  Daria Grafodatskaya; Cheryl Cytrynbaum; Rosanna Weksberg
Journal:  EMBO Rep       Date:  2013-01-22       Impact factor: 8.807

7.  ISMAAR: Leading the global agenda for a more physiological, patient-centred, accessible and safer approaches in ART.

Authors:  Geeta Nargund; R C Chian
Journal:  J Assist Reprod Genet       Date:  2013-02       Impact factor: 3.412

8.  Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2015-08-21       Impact factor: 4.234

9.  Anti-Müllerian hormone is all you need: an assisted reproductive technology perspective in diagnosing polycystic ovary syndrome.

Authors:  Kate McCullough; William Ledger
Journal:  Womens Health (Lond)       Date:  2016-05-11

Review 10.  The state of "freeze-for-all" in human ARTs.

Authors:  Natalia Basile; Juan A Garcia-Velasco
Journal:  J Assist Reprod Genet       Date:  2016-09-14       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.